Literature DB >> 26435289

PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.

Amanda Black1, Wen-Yi Huang, Patrick Wright, Tom Riley, Jerome Mabie, Sunitha Mathew, Lawrence Ragard, Sigurd Hermansen, Kelly Yu, Paul Pinsky, Philip C Prorok, Neal D Freedman, Robert N Hoover.   

Abstract

The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a large-scale, multi-institutional, randomized controlled trial, was launched in 1992 to evaluate the effectiveness of screening modalities for prostate, lung, colorectal, and ovarian cancer. However, PLCO was additionally designed to serve as an epidemiologic resource and the National Cancer Institute has invested substantial resources over the years to accomplish this goal. In this report, we provide a summary of changes to PLCO's follow-up after conclusion of the screening phase of the trial and highlight recent data and biospecimen collections, including ancillary studies, geocoding, administration of a new medication use questionnaire, consent for linkage to Medicare, and additional tissue collection that enhance the richness of the PLCO resource and provide further opportunities for scientific investigation into the prevention, early detection, etiology and treatment of cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26435289      PMCID: PMC6444921          DOI: 10.2174/157488711003150928130654

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  8 in total

1.  Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.

Authors:  Tracy M Layne; Stephanie J Weinstein; Barry I Graubard; Xiaomei Ma; Susan T Mayne; Demetrius Albanes
Journal:  Cancer       Date:  2017-04-03       Impact factor: 6.860

2.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Authors:  Paul F Pinsky; Philip C Prorok; Kelly Yu; Barnett S Kramer; Amanda Black; John K Gohagan; E David Crawford; Robert L Grubb; Gerald L Andriole
Journal:  Cancer       Date:  2016-12-01       Impact factor: 6.860

3.  Risk assessment for PFOA and kidney cancer based on a pooled analysis of two studies.

Authors:  K Steenland; J N Hofmann; D T Silverman; S M Bartell
Journal:  Environ Int       Date:  2022-07-22       Impact factor: 13.352

4.  Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.

Authors:  Amy P N Skubitz; Kristin L M Boylan; Kate Geschwind; Qing Cao; Timothy K Starr; Melissa A Geller; Joseph Celestino; Robert C Bast; Karen H Lu; Joseph S Koopmeiners
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-01

5.  Potential Disparities by Sex and Race or Ethnicity in Lung Cancer Screening Eligibility Rates.

Authors:  Paul F Pinsky; Yan Kwan Lau; Chyke A Doubeni
Journal:  Chest       Date:  2021-02-03       Impact factor: 10.262

6.  Immune factors preceding diagnosis of glioma: a Prostate Lung Colorectal Ovarian Cancer Screening Trial nested case-control study.

Authors:  Ivo S Muskens; Mi Zhou; Lucie Mccoy; Paige M Bracci; Helen M Hansen; W James Gauderman; John K Wiencke; Margaret R Wrensch; Joseph L Wiemels
Journal:  Neurooncol Adv       Date:  2019-09-29

7.  Relative impact of genetic ancestry and neighborhood socioeconomic status on all-cause mortality in self-identified African Americans.

Authors:  Hari S Iyer; Scarlett Lin Gomez; Iona Cheng; Timothy R Rebbeck
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

8.  A multiplex platform for the identification of ovarian cancer biomarkers.

Authors:  Kristin L M Boylan; Kate Geschwind; Joseph S Koopmeiners; Melissa A Geller; Timothy K Starr; Amy P N Skubitz
Journal:  Clin Proteomics       Date:  2017-10-10       Impact factor: 3.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.